LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Rhythm Pharmaceuticals Inc

Închisă

SectorSănătate

62.25 1.75

Rezumat

Modificarea prețului

24h

Curent

Minim

60.56

Maxim

62.73

Indicatori cheie

By Trading Economics

Venit

-6.2M

-49M

Vânzări

-9.1M

33M

EPS

-0.81

Marjă de profit

-151.352

Angajați

283

EBITDA

-9.5M

-47M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+35.77% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-21M

4.1B

Deschiderea anterioară

60.5

Închiderea anterioară

62.25

Sentimentul știrilor

By Acuity

34%

66%

90 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 iun. 2025, 20:51 UTC

Câștiguri

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 iun. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 iun. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 iun. 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 iun. 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 iun. 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 iun. 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 iun. 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 iun. 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 iun. 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 iun. 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 iun. 2025, 18:39 UTC

Market Talk
Câștiguri

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 iun. 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 iun. 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 iun. 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 iun. 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 iun. 2025, 17:08 UTC

Câștiguri

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 iun. 2025, 16:52 UTC

Achiziții, Fuziuni, Preluări

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 iun. 2025, 16:22 UTC

Câștiguri

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 iun. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27 iun. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 iun. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27 iun. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27 iun. 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 iun. 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparație

Modificare preț

Rhythm Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

35.77% sus

Prognoză pe 12 luni

Medie 83.42 USD  35.77%

Maxim 94 USD

Minim 72 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRhythm Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

12

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

60 / 65.58Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

90 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.